Cidara Net Income from 2010 to 2026
| CDTX Stock | USD 221.38 0.06 0.03% |
Net Loss | First Reported 2013-12-31 | Previous Quarter -25.7 M | Current Value -83.2 M | Quarterly Volatility 18.2 M |
Check Cidara Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Cidara Therapeutics' main balance sheet or income statement drivers, such as Depreciation And Amortization of 378.7 K, Selling General Administrative of 13.2 M or Other Operating Expenses of 214.2 M, as well as many indicators such as Price To Sales Ratio of 126, Dividend Yield of 0.0 or PTB Ratio of 0.99. Cidara financial statements analysis is a perfect complement when working with Cidara Therapeutics Valuation or Volatility modules.
Cidara | Net Income | Build AI portfolio with Cidara Stock |
Latest Cidara Therapeutics' Net Income Growth Pattern
Below is the plot of the Net Income of Cidara Therapeutics over the last few years. Net income is one of the most important fundamental items in finance. It plays a large role in Cidara Therapeutics financial statement analysis. It represents the amount of money remaining after all of Cidara Therapeutics operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue. It is Cidara Therapeutics' Net Loss historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Cidara Therapeutics' overall financial position and show how it may be relating to other accounts over time.
| View | Last Reported (169.83 M) | 10 Years Trend |
|
Net Income |
| Timeline |
Cidara Net Income Regression Statistics
| Arithmetic Mean | (52,260,670) | |
| Coefficient Of Variation | (103.90) | |
| Mean Deviation | 40,136,984 | |
| Median | (41,092,000) | |
| Standard Deviation | 54,300,372 | |
| Sample Variance | 2948.5T | |
| Range | 169M | |
| R-Value | (0.79) | |
| Mean Square Error | 1164.2T | |
| R-Squared | 0.63 | |
| Significance | 0.0001 | |
| Slope | (8,533,862) | |
| Total Sum of Squares | 47176.5T |
Cidara Net Income History
Other Fundumenentals of Cidara Therapeutics
| Net Income From Continuing Ops | ||
| Net Income Applicable To Common Shares | ||
| Net Income Per Share | ||
| Net Income Per E B T |
Cidara Therapeutics Net Income component correlations
About Cidara Therapeutics Financial Statements
Cidara Therapeutics investors use historical fundamental indicators, such as Cidara Therapeutics' Net Income, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Cidara Therapeutics. Please read more on our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Net Loss | -152.8 M | -145.2 M | |
| Net Loss | -153.3 M | -145.6 M | |
| Net Loss | -26.8 M | -28.2 M | |
| Net Loss | (24.07) | (25.27) | |
| Net Income Per E B T | 1.15 | 1.07 |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Cidara Stock Analysis
When running Cidara Therapeutics' price analysis, check to measure Cidara Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Cidara Therapeutics is operating at the current time. Most of Cidara Therapeutics' value examination focuses on studying past and present price action to predict the probability of Cidara Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Cidara Therapeutics' price. Additionally, you may evaluate how the addition of Cidara Therapeutics to your portfolios can decrease your overall portfolio volatility.